The Feasibility of Using Cannabis in Veterinary Medicine

List all Project Mentors & Advisor(s)

Dr. William DeWees

Presentation Format

Poster Presentation

Abstract/Description

With discussions surrounding the legalization of cannabis for medicinal and recreational purposes gaining popularity within the United States, this presentation will look at the benefits and risks of using plants within the Cannabis genus in veterinary medicine. The viability of cannabis use as compared to drugs currently used to treat symptoms such as poor appetite and seizures will occur in order to determine if it is feasible for Cannabis sativa to gain a place in conventional veterinary practices. A focus on hemp, a variety of Cannabis sativa that produces less than 0.3% THC, will occur in light of the recent research permits granted within the state of Kentucky. Comparisons between cannabis administration to patients and the administration of current drugs of choice will be made on the basis of efficacy, cost, and known risks.

Location

Small Ballroom, Curris Center

Start Date

April 2016

End Date

April 2016

Affiliations

Honors Thesis

This document is currently not available here.

Share

COinS
 
Apr 20th, 10:00 AM Apr 20th, 11:30 AM

The Feasibility of Using Cannabis in Veterinary Medicine

Small Ballroom, Curris Center

With discussions surrounding the legalization of cannabis for medicinal and recreational purposes gaining popularity within the United States, this presentation will look at the benefits and risks of using plants within the Cannabis genus in veterinary medicine. The viability of cannabis use as compared to drugs currently used to treat symptoms such as poor appetite and seizures will occur in order to determine if it is feasible for Cannabis sativa to gain a place in conventional veterinary practices. A focus on hemp, a variety of Cannabis sativa that produces less than 0.3% THC, will occur in light of the recent research permits granted within the state of Kentucky. Comparisons between cannabis administration to patients and the administration of current drugs of choice will be made on the basis of efficacy, cost, and known risks.